Evidence
A patented, published method, clinical data partnerships and a closed seed round.
The patented and peer-reviewed science, data access, funding and collaborations behind our models.
- Whole-slide images
- 2M+Available for model training and validation
- Data partners
- NHSNHS Greater Glasgow & Clyde and the NHS West of Scotland Innovation Hub
- Method
- PatentedAnd published in Nature Communications
- Seed round
- £2.261MLed by Twin Path Ventures
Partners and investors
Institutional and investor backing
TileBio closed a £2.261M seed round led by Twin Path Ventures, with Maven Capital Partners, Scottish Enterprise, the University of Glasgow and the Smart Things Accelerator Centre. Our data partnership is with NHS Greater Glasgow & Clyde and the NHS West of Scotland Innovation Hub.
Patented and peer-reviewed
The method is patented and published
Nature Communications, 2024
Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides
Quiros et al., Nature Communications 15, 4596 (2024). The histomorphological phenotype learning method underpinning our foundation model is patented, peer-reviewed and open access. In lung cancer, the learned phenotypes align with patient survival, recognised tumour types and growth patterns, and transcriptomic measures of immunophenotype, and these properties hold in a multi-cancer study. TileBio co-founders Ke Yuan and John Le Quesne are authors.
Read the paper on nature.comInternal validation
Tested against known morphology and public datasets
Internal study
We have benchmarked the model against established growth patterns and public whole-slide datasets. These are internal studies and are reported as such.
Collaborations
Collaborations and pilots
Terrain Life Science
In September 2025 TileBio and Terrain Life Science announced a collaboration combining Terrain’s hyperplex immunofluorescence spatial proteomics with TileBio’s H&E and multiplex immunofluorescence models, for biomarker discovery and diagnostic development. We are also engaging with global pharmaceutical companies on toxicology and discovery pilots, and will publish details once agreements are in place.
Become an early partner
Early partners help shape the direction of model development.